Eli Lilly wants a nuclear backup plan

Not your usual AI power play

Everyone’s been talking about nuclear like it’s the new fuel for hyperscale AI. Eli Lilly just gave the storyline a pharma twist. The drugmaker says it’s exploring nuclear energy with Indiana, signing a letter of intent to support small modular reactors and advanced nuclear technology.

Why should you care?

Because pharma factories are not like cloud servers. A data center can juggle workloads and reroute traffic; a drug manufacturing line is a more delicate beast. It needs steady power, predictable operations, and basically zero drama. Nuclear, at least in theory, checks those boxes.

The bigger move here

This also hints at a broader shift: nuclear isn’t just a Silicon Valley power fantasy anymore. Industrial players like Lilly want reliability, and that means the atomic conversation is moving from “cool future tech” to “how do we avoid going dark?”

The reality check

Of course, this whole sector comes with a giant asterisk. Nuclear projects are notoriously hard to build, finance, and permit. So while Lilly’s move is a meaningful signal, it’s still more roadmap than runway.

Big picture: if AI made nuclear trendy, industrial companies like Lilly may end up making it actually useful.